Navigation Links
Beckman Coulter to Acquire Siemens Healthcare Diagnostics' Clinical Microbiology Business
Date:7/16/2014

BREA, Calif., July 16, 2014 /PRNewswire/ -- Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announced today that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics.

The Siemens clinical microbiology business is an established leader in microbial identification and antibiotic sensitivity testing (ID/AST). The business operates with an installed base of over 6,000 instruments globally. The microbiology product line includes the MicroScan® Instruments and MicroScan® panels/consumables, along with data management solutions. The MicroScan systems are recognized in their industry for their high accuracy and superior detection of emerging resistance.

Beckman Coulter Diagnostics President Arnd Kaldowski said, "The clinical microbiology business will be an excellent complement to Beckman Coulter's Diagnostics business with a strong reputation and market position. Adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care. The acquisition expands our product portfolio with differentiated analytical systems and menu that elevate our clinical capabilities for customers, while driving continued growth."

The transaction is expected to close in Q1 2015. The agreement is subject to applicable regulatory approvals and other customary closing conditions.

About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Based in Brea, Calif., Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For more than 75 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes – offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation and information systems. Beckman Coulter is, and always has been, singularly devoted to moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.

Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of the clinical microbiology business of Siemens Healthcare Diagnostics, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined company and any other statements about managements' future expectations, beliefs, goals, plans or prospects, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: general economic conditions and conditions affecting the industries in which the clinical microbiology business operates; the uncertainty of regulatory approvals; the parties' ability to satisfy the closing conditions and consummate the transaction; Beckman Coulter's ability to successfully integrate the clinical microbiology business' operations and employees with its existing business; and the ability to realize anticipated growth, synergies and cost savings.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher Corporation's SEC filings, including its 2013 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2014. These forward-looking statements speak only as of the date of this release and neither Beckman Coulter nor Danaher assumes any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Beckman Coulter and the stylized logo are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.Contacts:

Mary LuthyBeckman Coulter Company CommunicationsPhone: 714-961-6364Email: mluthy@beckman.comLaura BrightBeckman Coulter Diagnostics Public Relations Phone: 714-961-3909 Email: llbright@beckman.com Logo - http://photos.prnewswire.com/prnh/20031202/BECLOGO


'/>"/>
SOURCE Beckman Coulter
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Atonomics Achieves Significant Milestone Related to Performance Data for Troponin I Assay Triggering Scheduled Payments From Beckman Coulter
2. Beckman Coulter Receives FDA Clearance of AccuTnI+3 Troponin I Assay on UniCel DxI Immunoassay Systems
3. Mindray Announced a Settlement Agreement with Beckman Coulter Inc
4. Apex BioStrategists Advises On Flow Cytometry Sale To Coulter
5. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
6. Watson to Acquire Actavis Group for EUR4.25 Billion
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
9. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
10. Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash
11. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... has named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of ... specializes in providing information destruction , recycling, and compliance services to ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
(Date:4/21/2017)... ... , ... The staff at Palm Beach Face is proud to announce that their practice founder, ... Set to take place on April 23rd, the London Marathon has a long tradition of ... part of team EMPOWER, raising money for the international charity, Smile Train. , ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its ... that the full potential of specialty and orphan brands can only be achieved when ... , “The Unifying Effect is at the heart of a true partnership between our ...
Breaking Medicine News(10 mins):